key: cord-0716527-0gzhjgfa
authors: Neto, Felippe Lazar; Salzstein, Guilherme A.; Cortez, André L.; Bastos, Thaís L.; Baptista, Fabíola V.D.; Alves, Joanne; Lauterbach, Gerhard P.; de Oliveira, Julio Cesar; de Assis, Fábio C.; Aguiar, Marília R.A.; de Deus, Aline A.; Dias, Marcos Felipe D.S.; Sousa, Felipe C.B.; Duailibi, Daniel F.; Kondo, Rodrigo H.; de Moraes, Augusto C.F.; Martins, Milton A.
title: Comparative Assessment of Mortality Risk Factors Between Admission and Follow-up Models Among Patients Hospitalized with COVID-19
date: 2021-03-09
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.03.013
sha: 59ed1b2719cde23ad3706058037d9031fec2de8d
doc_id: 716527
cord_uid: 0gzhjgfa

OBJECTIVES: We aim to compare differences in mortality risk factors between admission and follow-up incorporated models. METHODS: A retrospective cohort study with 524 patients with confirmed COVID-19 infection admitted to a tertiary medical center in São Paulo, Brazil, from March 13(th) to April 30(th), 2020. We collected data at admission, 3(rd), 8(th) and 14(th) day of hospitalization. We calculated the hazard ratio (HR) and compared 28-day in-hospital mortality risk factors between admission and follow-up models using a time-dependent Cox regression model. RESULTS: Of 524 patients, 50.4% needed mechanical ventilation. The 28-day mortality rate was 32.8%. Compared to follow-up, admission models under-estimated the mortality HR for peripheral oxygen saturation<92% (1.21 versus 2.09), heart rate>100bpm (1.19 versus 2.04), respiratory rate>24ipm (1.01 versus 1.82) and mechanical ventilation (1.92 versus 12.93). Low oxygen saturation, higher oxygen support and more biomarkers including lactate dehydrogenase, c-reactive protein, neutrophil-lymphocyte ratio and urea remained associated with mortality after adjustment for clinical factors at follow-up compared to only urea and oxygen support at admission. CONCLUSIONS: The inclusion of follow-up measurements changed mortality hazards of clinical signs and biomarkers. Low oxygen saturation, higher oxygen support, lactate dehydrogenase, c-reactive protein, neutrophil-lymphocyte ratio and urea could help prognose patients during follow-up.

The SARS-CoV-2 virus has infected more than 100 million and killed nearly 2.5 million people worldwide over the past several months (JHU, 2020) . Although most patients will be asymptomatic or have mild symptoms, over 10% of them will require hospitalization and 5% advanced medical support (Wu and McGoogan, 2020) . Early identification of severe cases that will demand longer hospitalizations and increased costs can help guide medical decisions and manage hospital resources, especially in economically deprived areas.

Clinical risk factors associated with disease progression and death(Center for Diseases Control, 2020, Giannouchos et al., 2020 , Tian et al., 2020 , Wang et al., 2020 identified in observational studies include older age, hypertension, diabetes, cardiovascular disease, pulmonary disease, chronic renal disease, and cancer.

Although there is conflicting evidence about the relative risk of some (e.g., hypertension (Tadic et al., 2020) ), a lack of morbidities seems to be protective. Male gender (Boulle et al., 2020 , Palaiodimos et al., 2020 and non-white ethnicity (Sze et al., 2020) have also been associated with mortality in some studies.

Among patients hospitalized with COVID-19, several biomarkers have been associated with poor outcomes (Malik et al., 2020 , Rod et al., 2020 . Non-survivors have been shown to have lower lymphocyte counts and higher levels of dimer-D, c-reactive protein, lactate dehydrogenase and interleukin-6 on admission compared to discharged patients. However, few studies have taken into consideration subsequent (from admission) biomarkers levels (Berzuini et al., 2020 , Ye et al., 2020 and consequently there is limited validity of their prognostic ability for posterior reassessments during a hospital stay. In addition, only a few biomarkers remain associated after adjustment for clinical factors.

Although more than 20 million people have been infected by COVID-19 in Latin America(JHU, 2020), we lack clinical information on patients' characteristics and outcomes in this region. The goals of this article are:(i) to describe the profile of patients admitted with COVID-19 infection to the largest tertiary publicly-funded hospital in Brazil during the first two months of the coronavirus pandemic and (ii) to compare the predictive performance and measures of association between a model with only admission variables and another with the inclusion of repeated measurements throughout hospitalization.

We carried out a retrospective cohort study on consecutive patients diagnosed with SARS-CoV-2 infection admitted to Hospital das Clínicas, a University of São Paulo affiliated institution, from March 13 th to April 30 th , 2020. SARS-CoV-2 infection was confirmed after a positive real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) test on a nasopharyngeal or tracheal swab test. During the aforementioned period, Hospital das Clínicas was included in the regional COVID-19 plan to receive only highly suspected or confirmed cases in need of advanced care support not available at the origin (e.g. renal replacement therapy). An assessment algorithm that included the Sequential Organ Failure Assessment (SOFA) and expected long-term survival was used for prioritization of beds. The institutional protocol recommended antibiotics (if pneumonia) and prophylactic anticoagulation; hydroxychloroquine and corticosteroids were optional. We have excluded patients with ≤ 24 hours hospitalizations, admission diagnoses other than COVID-19, and patients < 18 years old. Only the first admission was considered in cases which more than one was observed. The final cohort included 524 admissions, and the project was approved by the National Ethics Committee under research protocol no. 31090720.0.0000.0068.

We retrieved all clinical information on demographics, medical morbidities and clinical follow-up from electronic health records through a standardized form. We collected the following variables from admission: symptoms, time from symptom onset, vital signs, oxygen support, and laboratory exams. Oxygen support was categorized into J o u r n a l P r e -p r o o f four groups reflecting different levels of oxygen dependency: room air, nasal catheter, intermediate oxygen support (Venturi mask, non-rebreather masks, BiPAP and highflow nasal cannula) and mechanical ventilation. Previously known comorbidities and regular medications were manually retrieved throughout hospitalization. We considered obesity diagnosis from medical headers because data on weight and height were mostly missing. To analyze the effects of clinical follow-up on mortality, we also collected vital signs, laboratory exams and current oxygen support on the 3 rd , 8 th and 14 th day of hospitalization. We chose these days to reflect both a short and long period of follow-up from admission. We standardized vital signs collection to the first measurement after 6:00 a.m., except for temperature, which was instead the highest measure of the day.

We collected daily medical prescriptions in the first 14 days following admission and re-classified them into major groups when more than one single agent was prescribed (e.g. intravenous corticosteroids). To examine the rates of unfractionated heparin (UFH) and low molecular weight heparin (LMWH) dosage prescriptions, we divided the prescribed dosage into three groups during data collection: prophylactic (subcutaneous UFC≤15.000 IU/day or subcutaneous LMWH≤40mg/day); optimized (subcutaneous UFC>15.000 or subcutaneous LMWH>40mg/day and <2mg/kg/day) and anticoagulation (intravenous UFC or subcutaneous LMWH ≥2mg/kg/day).

Our primary outcome was 28-day mortality. Patients still hospitalized at 28-days were considered alive. Secondary outcomes included overall mortality, thrombotic complications (stroke, myocardial infarction, deep vein thrombosis and pulmonary thromboembolism) and need for renal replacement therapy (RRT).

Categorical variables were described with the absolute number and respective percentage, and continuous variables with the median, mean, standard deviation (SD) or interquartile range (IQR) according to variable distribution. We used Kaplan-Meier survival curves with the inverse probability weights failure function to describe the occurrence of deaths on the 28th day of hospitalization (dependent variable). The covariates to be tested (independent variables) were selected based on prior knowledge and vital signs were categorized (e.g. temperature>=37.8) to account for possible nonlinear associations. We also categorized ethnicity as white and non-white due to the small number of sub-groups within the non-white category. To analyze the effects of follow-up variables on mortality, we have created two models: one solely based on admission variables, and another with the inclusion of repeated measurements of clinical vital signs and laboratory exams during hospitalization (days 3, 8 and 14). To model the latter, we used a time-dependent-covariates Cox model (Therneau et al., 2020) in which a new time-interval is created after a new measurement is added and an event (mortality) can happen at every end of an interval. Following this approach, a given subject can have multiple observations but will not have overlapping intervals and consequently the model is spared from within-subject correlation. We did not investigate J o u r n a l P r e -p r o o f medication prescription and outcomes because for most medications studied, there are already ongoing clinical trials (state-of-art for causal inference) that will ultimately clarify their role in COVID-19 treatment.

Univariable cox regressions were run for each covariate against the outcome for both admission and time-dependent variables. All covariates with a p-value≤0.20 were included in a multivariable model for confounding adjustment following a hierarchical framework approach from distal (age, ethinicity and sex) to proximal (vital signs and laboratoray exams) determinants. If after the inclusion the variable maintained a p-value≤0.20, it was kept in the model; otherwise, it was discarded from subsequent models. Exceptions included age, sex and ethnicity that were included in all models, and vital signs that were tested in the multivariable model regardless of the univariable statistical value. A baseline model with age, sex, ethnicity and comorbidities was first created, and then two subsequent models (admission and follow-up) were built upon it.

We present the final models in the article and all intermediate ones in the supplementary material. Cox proportional hazard assumption was evaluated using Schoenfeld residuals and model performance with Harrell's c-statistic.

We found few missing values (<5%) for most clinical variables except previous medications and laboratory exams (Supplemental Tables 1 and Table 2 ). We used a complete-case analysis in the article but provided a sensitivity analysis with imputation in the supplementary material. We performed multiple imputation with chained equations (MICE) and used Rubin's rules (Rubin, 2004) to combine results over ten imputed datasets. Because of the repeated measurements, imputation followed a multilevel procedure with the participant identification as a cluster for mixed effects.

Discrepancies between complete-case and imputation analysis are reported throughout the paper. The alpha was set at 5% (two-tailed). Statistical analysis was done in R version 3.6.2 (R Core Team 2013) using the mice (Buuren…, 2010) and survival package (Therneau, 2020) .

Table 1 describes patients' characteristics at admission and their hospitalization outcomes. Of 524 patients, the mean age was 58.7 years (SD 16.4) and most were male (57.44%) and with white skin color (68.46%). One quarter had smoking exposure.

The most common comorbidity was hypertension (59.25%) followed by diabetes (38.58%) and obesity (24.8%). Over one third of the patients were taking an angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB) before admission. Many patients had active cancer (13.78%) or previous solid organ transplant (3.94%). The median time from symptoms onset to admission was 7 days.

Patients had high respiratory rates and low peripheral oxygen saturation in addition to low lymphocytes counts and high levels of dimer-D, C-reactive protein and lactate dehydrogenase (LDH) on admission.

Over 24% of the patients were admitted already on mechanical ventilation and nearly half of them were intubated during hospitalization. The median (IQR) duration of mechanical ventilation was 10 (5-18) days. Nearly 60% (333) were transferred to intensive care units and of those, 50% died. Thrombotic events were observed in 9.7% of the patients and common complications included deep vein thrombosis (4.21%) and J o u r n a l P r e -p r o o f pulmonary thromboembolism (3.05%). The median (IQR) length of hospitalization was 12 (6-21) days. The 28-day in-hospital mortality rate was 32.82% and 36.92% died during hospitalization. Figure 1 shows the survival probability Kaplan-Meyer curve. Table 2 shows the medications prescribed and their length of prescription during the first 14 days after admission. Over 80% of the patients received ceftriaxone and azithromycin, and more than 65% oseltamivir as antibiotics. The majority of patients (≥ 50%) received regular prophylactic dosage of lower molecular weight heparin (LMWH) or unfractionated heparin (UFH); and nearly 30% received either optimized or anticoagulant dosage of LMWH. Few patients (< 5%) received hydroxychloroquine or ivermectin. Intravenous corticosteroids were administered to 44%. A high proportion of patients (44.3%) were prescribed neuromuscular blockade and, of those, half for more than four days. Norepinephrine was prescribed for 43% of the patients and opioids in nearly two-thirds of them. Table 3 shows both the univariable and final multivariable models for baseline comorbidities and 28-day in-hospital mortality. We found age, chronic kidney disease, cancer, stroke, chronic obstructive disease (COPD) and previous solid organ transplant associated with increased risk of mortality in the final multivariable model. Conversely, obesity was found to be protective. Both coronary artery disease and congestive heart J o u r n a l P r e -p r o o f failure were no longer associated after adjustment and sensitivity analysis showed similar results after imputation (Supplemental Table 3 ). 

Our study described the case-fatality rate and clinical correlates of mortality among a cohort of hospitalized patients with severe COVID-19 in the largest tertiary publicly-funded hospital in Brazil during the first two months of the coronavirus pandemic. In addition, we showed that the inclusion of repeated clinical and laboratorial measurements improves models' predictive performance and changes measures of association (hazard ratio) among correlates.

We observed a higher rate of overall mortality compared to tertiary centers in higher-income countries (Salacup et al., 2020 , Gregoriano et al., 2020 , Rieg et al., 2020 , Halem and Bruyndonckx…, 2020 . This can be partly explained by the higher prevalence of severe disease and need of invasive oxygen supplementation found in our cohort: nearly 50% of our patients needed mechanical ventilation support compared to only 12%, 19%, 22% and 26% of patients in similar centers in Belgium (Halem and Bruyndonckx…, 2020) , Switzerland (Gregoriano et al., 2020) , United States (Salacup et al., 2020) and Germany (Rieg et al., 2020) , respectively. Considering only those admitted to intensive care units (ICU), our mortality rate (50%) is comparable to Germany (47%) (Rieg et al., 2020) , lower than Russia (64%) (Moiseev et al., 2020) but higher than New York (22%) (Richardson et al., 2020) , Lombardy (26%) (Temel et al., 2010) and Belgium (38%) (Halem and Bruyndonckx…, 2020) . We also observed a lower rate of venous and arterial thrombosis compared to previous literature (Al-Ani et al., 2020) .

Prescription of antibiotics was very common (≥ 80%) and included mostly a combination of ceftriaxone and azithromycin in addition to oseltamivir. Over 45% of patients also received a second bacterial antibiotic during hospitalization. Our rates are J o u r n a l P r e -p r o o f higher than similar centers (Gregoriano et al., 2020 , Rieg et al., 2020 , Halem and Bruyndonckx…, 2020 and reflect the institutional protocol at that time. On the other hand, prescriptions of hydroxychloroquine, ivermectin and nitaxozamide were extremely low (< 5%), which contrasts with the large proportion of patients that were prescribed hydroxychloroquine in Switzerland (39%) (Gregoriano et al., 2020) , Germany (43%) (Rieg et al., 2020) , Italy (52%) (Fumagalli et al., 2020) and the United States (60%) (Salacup et al., 2020) . At that time, even though there was no evidence of a hydroxychloroquine benefit, it is noteworthy that many institutions worldwide routinely adopted its use during the initial months of the pandemic. The low prescription rate in our cohort can be explained by the lack of institutional recommendation and the skepticism regarding its use in a university-affiliated hospital. Interestingly, although the benefit of corticosteroids in COVID-19 was not proven at that time (Horby et al., 2020) , nearly 45% of the patients received intravenous corticosteroids and of those, at least half for five days or more.

Consistent with previous literature (Rod et al., 2020 , Wang et al., 2020 , we found older age, cancer, previous solid organ transplant, chronic renal disease, COPD and stroke were associated with increased mortality risk. We also have not observed any association between previous use of ARB or ACE and mortality (Zhang et al., 2020) .

Commonly reported risk factors for severe disease in general population studies such as hypertension, diabetes and male sex might have been underestimated because of the selection bias induced by including only tertiary hospitalized patients. In fact, selection and collider bias can ultimately lead to association distortions (attenuation, inflation or reversal) in observational studies (Griffith et al., 2020) and should prompt J o u r n a l P r e -p r o o f cautious interpretation of results. Similar reasoning can be applied to the protective effect of obesity. Although there is considerable evidence about the association of obesity and the higher risk of disease severity in COVID-19 patients (Palaiodimos et al., 2020 , Simonnet et al., 2020 , Tartof et al., 2020 , once the disease progresses, the estimated effect direction might change when only a subset of patients is considered (obesity paradox). Similar findings have been observed for coronary artery disease (Gruberg et al., 2002) and acute respiratory distress syndrome (Ni et al., 2017) and may be applicable to COVID-19; however, further studies are needed to answer this question.

Identifying patients at higher risk of death can guide medical decisions and help manage hospital resources, especially in an under-resourced setting. Many prognosisrelated factors have been identified for COVID-19; however, most of them rely on admission laboratory and clinical signs (Ou et al., 2020 , Wynants et al., 2020 , and consequently, have limited validity for posterior daily reassessments. In addition, it is expected that variables collected on admission change their prognostic ability when repeated measurements are included. As an example, we have shown that clinical signs hazards are under-estimated on admission compared to follow-up. This possibly happens because vital signs capture late changes ultimately associated with death (Bruera et al., 2014) that are under-represented on admission for most patients that will die much later during the course of disease. For instance, oxygen support (a proxy for respiratory deterioration) nearly doubled the hazards from admission because only 40% of all intubated patients were on mechanical ventilation at admission. Similar findings were observed for heart rate, respiratory rate and mean arterial pressure.

Similarly, laboratory tests help risk stratification but are prone to the same bias when only admission data are included. Consistent with prior literature (Malik et al., 2020 , Rod et al., 2020 , we have shown that most studied biomarkers were associated with mortality when unadjusted for clinical factors. However, because it is expected that clinical tests are ordered after clinical evaluation, it is imperative to consider their significance according to patients' past medical history and clinical signs (adjusted models). In this regard, we have shown that more markers were associated with mortality during follow-up (urea, CRP, neutrophil-lymphocyte ratio and LDH) compared to admission (urea) and might help physicians prognose patients during follow-up. Of those markers, the neutrophil-lymphocyte ratio had already been shown to have prognostic ability in a similar study with follow-up measurements (Berzuini et al., 2020) .

Notably, although widely requested on admission (>70%), we found no role for dimer-D in prognostication. Whether it can guide future therapies, such as for anticoagulation, remains a question and we have not found evidence for routine dosage.

Limitations are unavoidable and essential to discuss. First, this work presents a single-center experience that might not reflect the conditions found in private counterparts or primary and secondary settings. Second, our data represents the initial surge of the pandemic subject to the learning curve. Third, we have considered chart diagnosis for comorbidities and thus are prone to under-reporting or measurement error (obesity). Fourth, because of test unavailability, we did not have data on IL-6 levels which may have a role in prognosing COVID-19 infected patients. Finally, treatments were heterogeneous and we have not addressed medications prescriptions and outcomes. Strengths of our study include the detailed description of different outcomes J o u r n a l P r e -p r o o f and medications prescriptions rates among hospitalized patients from a tertiary public hospital in Brazil, and the analysis of follow-up measurements and their clinical interpretation for COVID-19 prognosis which few studies have taken into consideration before (Berzuini et al., 2020) .

In summary, we have described the clinical outcomes and patterns of prescription during the first two months of the pandemic in a tertiary center in Brazil. The incorporation of follow-up measurements, in addition to improving mortality prediction, changed the mortality hazards of vital signs and biomarkers compared to admission.

Peripheral oxygen saturation, oxygen support, LDH, urea, c-reactive protein and neutrophil-lymphocyte ratio, in addition to previously known comorbidities, can help prognose COVID-19 patients on follow-up assessments. 

Thrombosis risk associated with COVID-19 infection. A scoping review

Value of dynamic clinical and biomarker data for mortality risk prediction in COVID-19: a multicentre retrospective cohort study

Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa

Variations in vital signs in the last days of life in patients with advanced cancer

Multivariate imputation by chained equations in R

Center for Diseases Control. Coronavirus Resource

Clinical risk score to predict in-hospital mortality in COVID-19 patients: a retrospective cohort study

Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory-confirmed COVID-19 cases

Characteristics, predictors and outcomes among 99 patients hospitalised with COVID-19 in a tertiary care centre in Switzerland: an observational analysis

Collider bias undermines our understanding of COVID-19 disease risk and severity

The impact of obesity on the short-term and longterm outcomes after percutaneous coronary intervention: the obesity paradox

Risk factors for mortality in hospitalized patients with COVID-19 at the start of the pandemic in Belgium: a retrospective cohort study

Dexamethasone in hospitalized patients with Covid-19-preliminary report. The New England …

Johns Hopkins Coronavirus Resource Center

Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis

Outcomes of intensive care unit patients with COVID-19: a nationwide analysis in Russia

Can body mass index predict clinical outcomes for patients with acute lung injury/acute respiratory distress syndrome? A meta-analysis

Risk factors of severe cases with COVID-19: a meta-analysis

Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

COVID-19 in-hospital mortality and mode of death in a dynamic and non-restricted tertiary care model in Germany

A brief-review of the risk factors for covid-19 severity

Multiple imputation for nonresponse in surveys

Characteristics and clinical outcomes of COVID-19 patients in an underserved-inner city population: A single tertiary center cohort

High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation

Ethnicity and clinical outcomes in COVID-19: A systematic review and meta-analysis

COVID-19 and arterial hypertension: Hypothesis or evidence

Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization

Characteristics and outcomes of patients infected with SARS-CoV-2 admitted to. infection

A Package for Survival Analysis in R

Using time dependent covariates and time dependent coefficients in the cox model. Survival Vignettes

Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. The Lancet Oncology

Does comorbidity increase the risk of patients with COVID-19: evidence from meta-analysis

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal

Dynamic changes of D-dimer and neutrophil-lymphocyte count ratio as prognostic biomarkers in COVID-19

ACEI/ARB use and risk of infection or severity or mortality of COVID-19: a systematic review and meta-analysis

Urea (mg/dL), Median (IQR)

1000/mm3), Median (IQR)

Lactic Dehydrogenase (U/L), Median (IQR) 403.5

1%) UFH Anticoagulant 29 (5.53%) Days, Median (IQR) 2 (1-6) Days, Median (IQR) 4 (2-6) Fenoterol 30 (5.73%) NSAIDs

IQR) 3 (1.25-4) Days

-8) Days, Median (IQR) 4 (2-7) Norepinephrine 230 (43.89%) Erytropoietin 12 (2.29%) Days

The authors declare no competing interests.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.